J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it – Endpoints News
|
J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
Endpoints News A little more than three years ago, J&J stepped up with a $12.5 million upfront to rent a front row seat on Capricor Therapeutics' $CAPR Phase II stem cell study, looking to see if their off-the-shelf approach could mend a damaged heart. At the time … |
